|
A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. |
|
|
Honoraria - Millennium; Seagen |
Consulting or Advisory Role - Gilead Sciences; Janssen; Pfizer; Seagen |
Speakers' Bureau - Seagen; Takeda |
Research Funding - Abbott Laboratories (Inst); Biogen (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Piramal Life Science (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Gilead Sciences; Seagen |
Research Funding - AstraZeneca (Inst); Celgene (Inst); Genentech (Inst); Inanovate (Inst); Janssen Research & Development (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst) |
|
|
Stock and Other Ownership Interests - Merck |
Consulting or Advisory Role - BeiGene; Bullet Bio; Five Prime Therapeutics; ImmunoCellular Therapeutics; Inate Pharma; Kite, a Gilead company |
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Pharmacyclics (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MedImmune; Pfizer |
Research Funding - Bristol-Myers Squibb; MedImmune; Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Patents, Royalties, Other Intellectual Property - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |